Healthcare101

 The global pharmaceutical contract manufacturing market is witnessing strong momentum. Valued at USD 193.52 billion in 2024 , the market reached USD 209.90 billion in 2025 and is projected to grow at a robust CAGR of 8.2% between 2025 and 2030 — ultimately reaching USD 311.95 billion by 2030 . This steady expansion is driven by the increasing demand for GLP-1 manufacturing outsourcing , rising ADC outsourcing for commercialized biologics , and patent expiries of blockbuster drugs leading to a surge in biosimilar production . However, pricing pressure in the US and Europe and the high cost of regulatory compliance (Annex-1, PFAS restrictions) are anticipated to slightly restrain growth. Download PDF Brochure Market Overview: Emerging Opportunities and Regional Insights Asia Pacific: The Fastest-Growing Region The Asia Pacific region is expected to witness significant growth throughout the forecast period. Factors such as a large patient population , rising demand f...

 The global pharmaceutical contract manufacturing market continues its upward trajectory, driven by increasing outsourcing demand, rapid biologics expansion, and the push for cost-efficient, flexible production models. Valued at US$193.52 billion in 2024 , the market rose to US$209.90 billion in 2025 and is projected to reach US$311.95 billion by 2030 , advancing at a robust CAGR of 8.2% during the forecast period. As pharmaceutical manufacturers navigate complex global supply chains, evolving regulatory expectations, and accelerated drug development cycles, contract manufacturing organizations (CMOs/CDMOs) are emerging as essential partners for scalability, innovation, and operational resilience. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201524381 Why Contract Manufacturing Is Becoming a Cornerstone of Pharma Strategy The shift toward outsourcing is no longer solely cost-driven; it is increasingly rooted in strategic value creati...

 The global pharmaceutical contract manufacturing market growth forecasted to transform from USD 200.9 billion in 2024 to USD 319.6 billion by 2029, driven by a CAGR of 9.7%. Increasing use of generic drugs and funding, developments in the field of CMOs technology, the high cost of in-house drug discovery, and regulatory filing by the CMOs drive the growth of the pharmaceutical contract manufacturing market. Pharma CMOs using Al in drug development and manufacturing will bring efficiency and quality. In April 2024, Lonza launched its AI-powered Route Scouting Service: This service integrates Lonza's global expertise in the chemical supply chain with Elsevier Al technology (Reaxys) for the fast-tracking of artificial route identification for new APIs. Strict rules may limit the growth of the market. Moreover, applies AI in predictive analytics for supply chain management, planning efficient production schedules, and inventory levels. AI also optimizes clinical trials through incide...